Ironwood Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Ironwood Pharmaceuticals
IRWD Stock  USD 3.61  0.13  3.48%   
Ironwood Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ironwood Pharmaceuticals' valuation are provided below:
Gross Profit
201 M
Profit Margin
0.0811
Market Capitalization
609.8 M
Enterprise Value Revenue
3.0662
Revenue
296.2 M
There are over one hundred nineteen available fundamental trends for Ironwood Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Ironwood Pharmaceuticals' regular performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 2.1 B. The current year's Enterprise Value is expected to grow to about 2.4 B

Ironwood Pharmaceuticals Total Revenue

232.77 Million

Check Ironwood Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ironwood Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 20.9 M or Total Revenue of 232.8 M, as well as many indicators such as Price To Sales Ratio of 1.75, Dividend Yield of 0.0 or Days Sales Outstanding of 54.73. Ironwood financial statements analysis is a perfect complement when working with Ironwood Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Ironwood Stock
Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

Ironwood Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding143.5 M177.8 M144 M
Slightly volatile
Total Assets490.2 M396.9 M491.3 M
Slightly volatile
Short and Long Term Debt Total303.3 M212.8 M325.7 M
Slightly volatile
Other Current Liabilities247.9 M236.1 M59 M
Slightly volatile
Total Current Liabilities254.3 M242.2 M98.6 M
Slightly volatile
Other Liabilities8.3 M8.8 M41.6 M
Slightly volatile
Property Plant And Equipment Net18.8 M12.7 M22.5 M
Slightly volatile
Current Deferred Revenue1.7 M1.8 M9.6 M
Pretty Stable
Accounts Payable2.8 M2.9 M7.9 M
Slightly volatile
Cash202.6 M215.5 M203.9 M
Slightly volatile
Non Current Assets Total144.8 M122.7 M149.4 M
Slightly volatile
Non Currrent Assets Other4.3 M4.5 M47.5 M
Very volatile
Other Assets1.091.1573.3 M
Pretty Stable
Long Term Debt705.2 M671.6 M344.3 M
Slightly volatile
Cash And Short Term Investments271.2 M215.5 M264.4 M
Pretty Stable
Net Receivables62.6 M46.7 M66.4 M
Slightly volatile
Common Stock Total Equity125.3 K177.1 K136.4 K
Slightly volatile
Liabilities And Stockholders Equity490.2 M396.9 M491.3 M
Slightly volatile
Non Current Liabilities Total379.3 M209.6 M359.8 M
Slightly volatile
Other Current Assets9.6 M12 M8.8 M
Slightly volatile
Other Stockholder Equity1.1 B1.6 B1.2 B
Slightly volatile
Total Liabilities470.9 M451.8 M448.8 M
Slightly volatile
Property Plant And Equipment Gross20 M21.5 M24.1 M
Pretty Stable
Total Current Assets345.4 M274.2 M341.9 M
Slightly volatile
Short Term Debt3.1 M3.3 M26.8 M
Slightly volatile
Common Stock130.7 K184 K137.6 K
Slightly volatile
Property Plant Equipment5.4 M5.7 M17.2 M
Slightly volatile
Long Term Debt Total311.5 M455.7 M291.7 M
Slightly volatile
Capital Surpluse1.3 B1.6 B1.2 B
Slightly volatile
Capital Lease Obligations10.4 M17.8 M9.5 M
Slightly volatile
Deferred Long Term Liabilities13.2 M13.9 M34.3 M
Slightly volatile
Non Current Liabilities Other12.3 M15.4 M13.2 M
Pretty Stable
Short and Long Term Debt184.4 M229.5 M133.2 M
Slightly volatile
Long Term Investments12.5 M13.1 M58.5 M
Slightly volatile
Net Invested Capital400.9 M325.1 M381.4 M
Slightly volatile
Capital Stock173.6 K184 K158.5 K
Slightly volatile

Ironwood Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M1.9 M6.8 M
Slightly volatile
Interest Expense20.9 M32.7 M23.5 M
Slightly volatile
Total Revenue232.8 M296.2 M256 M
Slightly volatile
Other Operating Expenses297.2 M177.4 M314.2 M
Slightly volatile
Research Development106.1 M95.1 M103.3 M
Very volatile
Cost Of Revenue1.8 M1.9 M25.9 M
Pretty Stable
Total Operating Expenses279.9 M175.5 M294.7 M
Slightly volatile
Gross Profit226.7 M294.3 M237.6 M
Slightly volatile
Selling General Administrative140 M165.9 M136.2 M
Slightly volatile
Non Recurring16.8 M17.7 M23.7 M
Very volatile
Interest Income7.1 M4 M17.8 M
Slightly volatile
Reconciled Depreciation1.7 M1.8 M8.8 M
Slightly volatile

Ironwood Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation1.8 M1.9 M6.9 M
Slightly volatile
Capital Expenditures32.3 K34 K10 M
Pretty Stable
End Period Cash Flow195.8 M215.5 M203.4 M
Slightly volatile
Stock Based Compensation24 M17.2 M24.9 M
Slightly volatile
Begin Period Cash Flow84.1 M88.6 M187.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.751.845911.6523
Slightly volatile
Days Sales Outstanding54.7357.6122129
Slightly volatile
Stock Based Compensation To Revenue0.05530.05820.1574
Slightly volatile
Capex To Depreciation0.01720.01811.0825
Slightly volatile
EV To Sales1.751.836910.8174
Slightly volatile
Inventory Turnover0.971.0227.1359
Very volatile
Days Of Inventory On Hand672370699
Slightly volatile
Payables Turnover0.620.64917.0731
Pretty Stable
Sales General And Administrative To Revenue1.380.81.0715
Pretty Stable
Research And Ddevelopement To Revenue0.310.32121.3766
Slightly volatile
Capex To Revenue1.0E-41.0E-40.122
Slightly volatile
Cash Per Share1.261.32822.5127
Slightly volatile
Days Payables Outstanding53456217.2 K
Pretty Stable
Intangibles To Total Assets0.00490.00510.1156
Slightly volatile
Current Ratio1.081.13196.1055
Pretty Stable
Receivables Turnover6.026.335515.3845
Slightly volatile
Capex Per Share2.0E-42.0E-40.0958
Slightly volatile
Revenue Per Share1.521.82571.7232
Slightly volatile
Interest Debt Per Share1.621.51372.2963
Slightly volatile
Debt To Assets0.450.53620.6556
Slightly volatile
Graham Number7.829.355.3858
Slightly volatile
Operating Cycle54.7357.6122381
Slightly volatile
Days Of Payables Outstanding53456217.2 K
Pretty Stable
Ebt Per Ebit1.110.58961.0185
Slightly volatile
Quick Ratio1.081.13196.0566
Pretty Stable
Net Income Per E B T0.330.3430.6448
Very volatile
Cash Ratio0.850.88953.8758
Pretty Stable
Days Of Inventory Outstanding672370699
Slightly volatile
Days Of Sales Outstanding54.7357.6122129
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.460.99971.2673
Pretty Stable
Fixed Asset Turnover24.3923.231213.6359
Slightly volatile
Debt Ratio0.450.53620.6556
Slightly volatile
Price Sales Ratio1.751.845911.6523
Slightly volatile
Asset Turnover0.390.74620.5352
Slightly volatile
Gross Profit Margin0.720.99360.9027
Very volatile

Ironwood Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.1 B2 B1.9 B
Slightly volatile
Enterprise Value2.4 B2.2 B2.1 B
Slightly volatile

Ironwood Fundamental Market Drivers

Forward Price Earnings12.3305
Cash And Short Term Investments215.5 M

Ironwood Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ironwood Pharmaceuticals Financial Statements

Ironwood Pharmaceuticals stakeholders use historical fundamental indicators, such as Ironwood Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Ironwood Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ironwood Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ironwood Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ironwood Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.8 M1.7 M
Total Revenue296.2 M232.8 M
Cost Of Revenue1.9 M1.8 M
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 0.80  1.38 
Research And Ddevelopement To Revenue 0.32  0.31 
Revenue Per Share 1.83  1.52 
Ebit Per Revenue 0.40  0.42 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:
How To Invest In Ironwood
Details
Is Ironwood Stock a good investment?
Details
What is Ironwood Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Biotechnology sector continue expanding? Could Ironwood diversify its offerings? Factors like these will boost the valuation of Ironwood Pharmaceuticals. Market participants price Ironwood higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ironwood Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
10.468
Earnings Share
0.15
Revenue Per Share
1.83
Quarterly Revenue Growth
(0.47)
Return On Assets
0.1985
Investors evaluate Ironwood Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ironwood Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ironwood Pharmaceuticals' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Ironwood Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY